TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 89 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $402,000 | +6.9% | 130,920 | +119.5% | 0.35% | -26.1% |
Q4 2017 | $376,000 | +22.1% | 59,646 | +32.5% | 0.47% | +1023.8% |
Q3 2017 | $308,000 | +5.5% | 45,001 | +10.1% | 0.04% | -4.5% |
Q2 2017 | $292,000 | +137.4% | 40,885 | +54.4% | 0.04% | -74.0% |
Q1 2016 | $123,000 | – | 26,478 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 330,000 | $2,353,000 | 0.98% |
EcoR1 Capital, LLC | 633,400 | $4,516,000 | 0.80% |
DLD Asset Management, LP | 570,000 | $4,059,000 | 0.53% |
Rhenman & Partners Asset Management AB | 300,000 | $2,139,000 | 0.31% |
Eventide Asset Management | 600,000 | $4,278,000 | 0.27% |
Tekla Capital Management LLC | 1,004,322 | $7,161,000 | 0.26% |
Rock Springs Capital Management LP | 698,000 | $4,977,000 | 0.25% |
DLD Asset Management, LP | 230,000 | $1,640,000 | 0.21% |
Worth Venture Partners, LLC | 29,325 | $209,000 | 0.18% |
Crestline Management, LP | 161,403 | $1,151,000 | 0.15% |